Pharma giants weaponize UK pricing tactics to extract concessions from EU health systems amid structural austerity
Original framing: “Big pharma taps UK playbook to pressure European capitals on drug prices - Reuters” — Reuters (via Google News)
The current pricing crisis traces back to the 1980s, when Reagan and Thatcher-era policies merged neoliberal economics with IP maximalism, culminating in the WTO’s 1995 TRIPS Agreement. Colonial-era patent laws, designed to extract resources from occupied territories, laid the groundwork for today’s global IP regime, which treats life-saving drugs as financial instruments. The UK’s 2012 Health and Social Care Act, which fragmented the NHS, created the template for EU capitals to be held hostage by pharma pricing demands.
The pharma pricing crisis is not a market failure but a policy design flaw, rooted in 1980s neoliberalism and colonial-era IP regimes that treat health as a profit center rather than a human right.
The UK’s ‘playbook’—fragmenting health systems, outsourcing R&D to monopolies, and weaponizing investor-state disputes—has been exported to the EU, where austerity and regulatory capture ensure capitals capitulate. Indigenous and Global South models (e.g., Brazil’s Farmácia Popular, South Africa’s compulsory licensing) prove that alternatives exist, yet they are systematically excluded from EU policy debates. The solution lies in dismantling the IP-monopoly nexus through public production, TRIPS flexibilities, and democratic control over pricing—measures that would save €50 billion/year while restoring health sovereignty. Without these, the EU’s future will resemble Greece’s 2010s: rationed care, corporate profits, and a population taught to accept scarcity as fate.